Last reviewed · How we verify
Klimadynon
At a glance
| Generic name | Klimadynon |
|---|---|
| Sponsor | Scientific Research Institute of Public Health, Russian Federation |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women (PHASE4)
- Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS (PHASE4)
- Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients (PHASE1)
- Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints (PHASE3)
- Safety Study of Black Cohosh Use by Postmenopausal Women on the Liver (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Klimadynon CI brief — competitive landscape report
- Klimadynon updates RSS · CI watch RSS
- Scientific Research Institute of Public Health, Russian Federation portfolio CI